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Abstract
Background: RBBP6 is a 250 kDa splicing-associated protein that has been identified as an E3
ligase due to the presence of a RING finger domain. In humans and mice it interacts with both p53
and Rb, and plays a role in the induction of apoptosis and regulation of the cell cycle. RBBP6 has
recently been shown to be highly up-regulated in oesophageal cancer, and to be a promising target
for immunotherapy against the disease.
Results: We show here using heteronuclear NMR that the N-terminal 81 amino acids of RBBP6
constitute a novel ubiquitin-like domain, which we have called the DWNN domain. The domain
lacks conserved equivalents of K48 and K63, although the equivalents of K6 and K29 are highly,
although not absolutely, conserved. The di-glycine motif that is characteristic of proteins involved
in ubiquitination is found in the human and mouse form of the domain, although it is not present in
all organisms. It forms part of a three-domain form of RBBP6 containing the DWNN domain, a zinc
knuckle and a RING finger domain, which is found in all eukaryotic genomes so far examined, in
the majority of cases at single copy number. The domain is also independently expressed in
vertebrates as a single domain protein.
Conclusion: DWNN is a novel ubiquitin-like domain found only at the N-terminus of the RBBP6
family of splicing-associated proteins. The ubiquitin-like structure of the domain greatly increases
the likelihood that RBBP6 functions through s o m e  f o r m  o f  u b i q u i t in-like modification.
Furthermore, the fact that the DWNN domain is independently expressed in higher vertebrates
leads us to propose that the domain may itself function as a novel ubiquitin-like modifier of other
proteins.
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Background
A number of screens have been undertaken to identify
proteins that interact with the tumour suppressor proteins
p53 and Rb. RBBP6 is one of the few proteins identified
that has been shown to interact with both p53 and Rb.
Three partial cDNA's from the full length RBBP6 transcript
were originally cloned and sequenced in different studies.
RBQ-1 [1], corresponding to residues 150–1146 of the
human protein, and PACT (p53 associated cellular pro-
tein, testis derived) [2], corresponding to residues 207–
1792, were cloned on the basis of their ability to bind Rb
and p53 in both human and mouse cells. P2P-R [3], cor-
responding to residues 199–1792, was cloned based on its
recognition by two antibodies specific for heterogeneous
nuclear ribonucleoproteins (hnRNPs). An alternatively
spliced form omitting residues 651–685, corresponding
to exon 16 of the full length gene, has also been reported
[1]. The HGMW-approved name Retinoblastoma binding
protein 6 (RBBP6) will be used for the complete protein
in what follows. Analysis of the RBBP6 locus on human
16p12.2 suggests that three major transcripts of 6.1, 6.0
and 1.1 kb occur, by a combination of alternative splicing
and alternative poly-adenylation. These transcripts
encode proteins of 1792, 1758 and 118 amino acids,
which have been designated RBBP6 isoforms 1, 2 and 3
respectively (Genbank:NP_008841, Gen-
bank:NP_061173, Genbank:NP_116015).
RBBP6 has been shown to suppress the binding of p53 to
DNA [2] and to block the binding of the adenovirus E1A
protein to Rb [1-3], suggesting that the interactions with
both tumour suppressor proteins are biologically rele-
vant. RBBP6 strongly localises to chromosomes during
mitosis and to nuclear speckles, which are believed to be
The domain structure of the RBBP6 family of proteins Figure 1
The domain structure of the RBBP6 family of proteins. RBBP6 homologues containing a DWNN domain, a zinc 
knuckle and a RING finger are found in all complete eukaryotic genomes analysed to date, including the single celled parasite E. 
cuniculi, in which it is very much reduced in size. In vertebrates and insects the protein includes a long C-terminal extension 
containing p53 and Rb-interaction domains in human and mouse. A short form consisting of the DWNN domain and a poorly 
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the main sites of activity for pre-mRNA splicing and
processing, during interphase [4,5]. Over-expression has
been shown to lead to cell cycle arrest and apoptosis [6-
10]. The yeast homologue, Mpe1p, forms part of the Yeast
Cleavage and Polyadenylation Factor and is essential for
the specific cleavage and polyadenylation of pre-mRNA
[11].
Recently it has been reported that RBBP6 is strongly up-
regulated in oesophageal cancer cells, and high levels of
expression correlate with higher rates of proliferation in
cultured oesophageal cancer cell and low survival rates in
cancer patients [4]. Cytotoxic T cells specific for RBBP6-
derived peptides were able to lyse oesophageal cancer cells
in culture, and to produce regression of oesophageal
tumours in mice xenograft models.
Despite its potential as an anti-cancer target and its appar-
ently close association with transcription and the cell
cycle, very little is known about the function of RBBP6. In
this report we describe the structure of the N-terminal
domain of the human RBBP6 protein (which we have
named the DWNN domain) and show that it adopts a
ubiquitin-like fold. Taken together with the presence of
the RING finger domain in all RBBP6 homologues, this
result suggests that RBBP6 may regulate pre-mRNA
processing proteins by covalently modifying them with a
ubiquitin-like moiety. Given that the DWNN domain is
expressed as a single domain protein in the vertebrates as
the isoform 3 form, the additional possibility exists that
the DWNN domain itself plays the role of the ubiquitin-
like modifier.
Results
The RBBP6 protein family
An investigation using promoter-trapping technology led
to the identification of a novel hamster gene homologous
to the human cDNA 21c4 (Genbank:T25012) [12]. This
was completely sequenced and shown to be a 0.9 kb
cDNA clone encoding a 118 amino acid protein (Rees et
al, unpublished). The corresponding gene was found to be
located on human chromosome 16p12.2, upstream of the
previously identified RBBP6/PACT/P2P-R gene. Analysis
of cDNA sequences showed that the sequence coded for
the previously unidentified N-terminus of the RBBP6 pro-
tein (Dlamini et al, in prep), which we have named the
DWNN domain. A number of complete RBBP6 cDNA
clones have now been sequenced (Genbank:AB112074,
Genbank:AB112075, Genbank:BC029352) and these
confirm the presence of three mRNA transcripts of 6.1, 6.0
and 1.1 kb, which occur as the result of a combination of
alternative splicing and alternative poly-adenylation. The
three transcripts encode proteins of 1792, 1758 and 118
amino acids, which have been designated RBBP6 isoforms
1, 2 and 3 respectively. (Genbank:NP_008841, Gen-
bank:NP_061173, Genbank:NP_116015)
Extensive BLAST searches [13] against all available
sequence data showed that the DWNN domain is found
only at the N-terminus of the RBBP6 family of proteins.
All of the identified RBBP6 homologues include the
DWNN domain, a CCHC zinc finger and a RING finger
domain and are found as single copy genes in all complete
eukaryotic genomes analysed to date (see Figure 1). The
three domain form is found in plants, protozoa, fungi and
microsporidia, although it is much reduced in size in the
single-celled parasite Encephalitozoon cuniculi, which has a
highly compacted genome and has been identified as
being close to the "minimal" eukaryotic organism [14].
The RBBP6 homologues in vertebrates and insects are
longer and include additional domains, including the Rb-
binding and p53-binding domains identified previously
[1-3]. However, there are no homologous sequences
present in prokaryotes.
The zinc finger is of the CCHC type, also known as a "zinc
knuckle" [15], which occurs in a number of mRNA-asso-
ciated proteins, including the splicing factors SLU7, h9G8
and hSF1 [16]. The zinc knuckle from SLU7 has been
shown to play an active role in preventing SLU7 from
shuttling between the nucleus and the cytosol during
mRNA processing [17]. RING fingers are typically found
in E3-ubiquitin ligases and have been shown to play an
essential role in the conjugation of ubiquitin and ubiqui-
tin-like moieties to protein substrates [18]. The RBBP6
RING domains have a C-X2-C-X11-C-C-X- [NS]-X2-C-X2-C-
X12-C-X2-C rather than the classical C3HC4 consensus,
which means they are either C4C4 or C3NC4-type RING
fingers, depending on which residues are involved in
coordinating the two zinc ions. C4C4 RING-like domains
have been found in the transcription-associated proteins
CNOT4 [19,20] and p44 [21], and despite its non-typical
consensus CNOT4 has also been shown to have ubiqui-
tin-ligase activity [20]. In addition to the conserved
cysteines, RBBP6 RING domains share the wider set of
conserved hydrophobic residues characteristic of U-box
domains [22]. These are even stronger predictors of ubiq-
uitin-conjugating function than the metal-chelating resi-
dues, since they are shared by a wider set of domains that
adopt the same fold and participate in ubiquitination
even in the absence of zinc ions.
In addition to the first three domains, human and mouse
RBBP6 both contain long C-terminal extensions contain-
ing a proline-rich domain (residues 337–349), an SR
domain (residues 679–773) and the Rb-binding (residues
964–1120) and p53-binding domains (residues 1142–
1727) reported previously [2,3]. Large C-terminal exten-
sions also occur in the D. melanogaster and  C. elegansBMC Structural Biology 2006, 6:1 http://www.biomedcentral.com/1472-6807/6/1
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homologues ([23], Genbank:AF132177, Gen-
bank:NP_492424) although we have not been able to
identify clear homologues of the SR, Rb binding and p53
binding domains in these proteins, nor is it known
whether they associate with homologues of p53 or Rb.
An alignment of DWNN homologues from a range of dif-
ferent eukaryotes is shown in Figure 2. These sequences
show no similarity to any other sequences in the database,
indicating that the domain represents a novel protein
motif that emerged soon after the emergence of eukaryo-
tes. This conclusion is consistent with a comparative
genomic study of proteins involved in RNA metabolism
[24] showing that the appearance of splicing factors and
RNA binding domains such as zinc knuckles coincides
with the development of pre-mRNA splicing soon after
the emergence of eukaryotes. This is in contrast to pro-
teins involved in basic transcription and translation,
many of which share common ancestors which pre-date
the divergence of eukaryotes and prokaryotes. In the light
of the low copy number at which the RBBP6 gene appears,
it is perhaps interesting that many proteins involved in
Sequence alignment of DWNN homologues from a range of eukaryotic genomes Figure 2
Sequence alignment of DWNN homologues from a range of eukaryotic genomes. The DWNN domain has been 
found in all eukaryotic genomes analysed to date, in the majority of cases at single copy number, but not in prokaryotes. The 
alignment was performed using ClustalX [39] and the diagram produced using Pfaat [49].BMC Structural Biology 2006, 6:1 http://www.biomedcentral.com/1472-6807/6/1
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RNA metabolism are also present at low copy number in
the genomes of many organisms, despite the high level of
conservation and the essential function they fulfil in the
organism [24].
In addition to forming part of the full-length RBBP6 pro-
tein, the DWNN domain is also expressed in vertebrates as
a small protein of 118–150 residues (RBBP6 variant 3)
containing a DWNN domain and a short C-terminal tail.
Preliminary analysis suggests that the short form is
present in all vertebrates but not in invertebrates, plants or
fungi. The sequence from residues 82–118 in human is
poorly conserved across species, suggesting that it may be
un-structured in vivo; this conclusion is supported by our
observation that this part of the protein is sensitive to pro-
teolysis when expressed recombinantly in bacteria,
whereas the DWNN domain (residues 1–81) is highly sta-
ble.
Determination of the structure of the DWNN domain
Residues 1–81 of human RBBP6, corresponding to the
DWNN domain, were expressed recombinantly in E. coli
and the structure determined using heteronuclear NMR.
Assignment of 99% of all non-labile protons and 90% of
13C and 15N resonances was achieved using standard triple
resonance protocols (for a review see [25]). A total of
1825 NOE-derived distance restraints were used in the
structure calculation, made up of 865 short range, 278
medium range and 685 long range restraints. Structural
data used in the calculation are summarised in Figure 3. A
backbone superposition of the 25 lowest-energy conform-
ers is shown in Figure 4A. The average of the pair-wise root
mean square deviations for residues 2–75 is 0.57 Å for all
backbone heavy atoms and 1.16 Å for all heavy atoms
respectively. Regions of secondary structure were identi-
fied in MOLMOL [26] using the built-in algorithm. The
number of restraints per residue and the associated local
RMSD across the family of structures are shown in Figure
5. As expected, regions of secondary structure correspond
to large numbers of long-range NOE's and small RMSD's.
The final family of structures have no distance-restraint
violations greater than 0.3 Å, no dihedral angle violations
greater than 5° and conform well to ideal covalent geom-
etry as determined using the programmes WHATCHECK
[27] and PROCHECK-NMR [28]. Statistics relevant to the
final family of structures are presented in Table 1.
Comparison of the representative DWNN structure
against the entire Protein Data Base using the Dali server
[29] reveals that it is most similar to human ubiquitin
(PDB:1UBI), and the N-terminal ubiquitin-like domain
of Isg15 (PDB:1Z2M), with Z-scores of 7.5 and 7.6 respec-
tively. The amino acid sequences of ubiquitin and DWNN
are only 18% identical. A superposition of the backbone
traces of the DWNN domain and ubiquitin is shown in
Figure 4C, along with a structural alignment of the pri-
mary sequences (Figure 4D). The RMSD between the two
structures over structurally equivalent regions (see Meth-
ods for details of structurally equivalent regions) is 1.88 Å.
The secondary structure consists of the elements β1-β2-β3-
α-β4- β5- β6- β7, with the α-helix packing against a five-
stranded β-sheet made up of strands β1, β2, β4, β5 and β7
in a ubiquitin-like β-grasp topology (see Figure 4B).
Unlike ubiquitin, DWNN contains an additional short
section of anti-parallel β-sheet immediately prior to the α-
helix (sheets β3 and β6, residues 23–25 and 63–65 respec-
tively), the evidence for which takes the form of strong
αN(i,i+1) NOE's and large 3JNα coupling constants (see
Figure 3). The residues in this sheet have the highest
Table 1: Statistics of the 25 lowest energy conformations
Restraints
NOE-derived restraints
short-range, |i-j|< = 1 865
medium-range, 1<|i-j|<5 297





Pairwise superposition of backbone atoms of residues 
2–75
RMSD over backbone heavy atoms 0.57 Å
RMSD over all heavy atoms 1.16 Å
Ramachandran plot appearance
Most favoured regions 92.32 +- 2.77
Generously allowed regions 6.74 +- 2.47
Generously allowed regions 0.62 +- 0.85
Disallowed regions 0.31 +- 0.57
Bad VDW contacts (PROCHECK) 0.00 +- 0.00
PROCHECK G-factors
Dihedrals -0.21 +- 0.05
Covalent 0.15 +- 0.03
Overall -0.09 +- 0.04
WHATCHECK Z-scores
1st generation packing quality -0.34 +- 0.18
2nd generation packing quality -1.79 +- 0.34
chi-1/chi-2 rotamer normality -2.10 +- 0.36
Backbone conformation -1.12 +- 0.47
Bond lengths 0.85 +- 0.02
Omega angle restraints 0.63 +- 0.05
Side chain planarity 0.86 +- 0.11
Improper dihedral distribution 0.75 +- 0.03
Inside/Outside distribution 1.10 +- 0.02BMC Structural Biology 2006, 6:1 http://www.biomedcentral.com/1472-6807/6/1
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number of long-range NOE's, and the some of the lowest
RMSD values (see Figure 5), suggesting that it is one of the
most stable regions of the whole protein. To our knowl-
edge this additional β-sheet has not been seen in other
ubiquitin-like proteins. The 310 helix immediately preced-
ing the last β-strand in many ubiquitin-like proteins is not
present in DWNN; Figure 4D shows that the residues cor-
responding to this helix (ubiquitin: 57–61, underlined in
Figure 4D) are entirely absent in DWNN. In addition,
based on our data we were not able to confirm the pres-
ence of a second 310 helix at the C-terminal end of the α-
helix that is found in many ubiquitin-like proteins; how-
ever the loop preceding strand β4 is two residues longer
than the corresponding loop in ubiquitin, so that there is
no longer a requirement for a tight helical turn at this
position. The high level of conservation of G21 (Figure 2)
may be the consequence of the presence of the extra
strand β3, which requires the backbone to make a sharp
kink at that position. Hydrophobic residues F8, L29, I33,
L39, L46, I64, V70, V72 and P76 make up the core of the pro-
tein, accounting for their high degree of conservation. The
high level of conservation of non-hydrophobic residues
Y6, K7, K30, Y57 and R74 suggests a possible functional role
for these residues.
Discussion
In recent years a superfamily of ubiquitin-like domains
has been identified [30]. This superfamily can be divided
into the ubiquitin-like proteins (UBL's), which consist
solely of the ubiquitin-like domain, and ubiquitin
domain proteins (UDP's), which are larger proteins con-
taining one or more ubiquitin-like domains. To our
knowledge DWNN is the first example of a ubiquitin-like
domain that is alternatively expressed both as a UBL and
as a UDP.
Ubiquitin-like proteins typically share the C-terminal GG
motif, which acts as a recognition motif for a protease that
cleaves between the two glycines, initiating the process of
conjugation. The occurrence of the GG motif in the struc-
turally identical position in human and mouse DWNN
domains (highlighted in pink in Figure 4D) suggests that
the domain may be involved in a similar process of con-
jugation, which we may call "DWNNylation". As in the
case of ubiquitin, the GG lies outside of the structured
region, as can be clearly seen in Figure 5B. The absence of
the GG in lower organisms is more difficult to rationalise;
however preliminary EST analysis suggests that organisms
which do not contain the GG motif also do not contain
the UBL form of the DWNN domain (unpublished data),
so it is possible that the DWNN domain does not act as a
covalent modifier in lower organisms. In the yeast protein
Hub1, which has also been shown to be involved in pre-
mRNA splicing [31], the role of the di-glycine motif is
taken by a YY motif [32]. The structurally equivalent posi-
tion in DWNN is taken by a highly conserved RR motif
(see Figure 2), which may therefore act as the activation
signal.
Ubiquitin contains four conserved lysine residues which
are the sites of attachment of additional ubiquitin moie-
ties, leading to the formation of poly-ubiquitin chains in
some contexts [33]. K48-linked chains are recognised by
the 26S proteosome, leading to degradation of the
attached protein, whereas K6-linked and K63-linked chains
are involved in a number of non-proteolytic processes,
including stress response, DNA repair and endocytosis
[34]. K11-linked and K29-linked chains may also target
substrates to the proteosome. In addition, mono-ubiqui-
tination of proteins has been shown to be associated with
receptor endocytosis, as well as the sorting and trafficking
of proteins [35]. The DWNN domain contains no equiva-
lent of K48 or K63 (see Figure 4D), although the equivalents
of K6 and K29 (K7 and K30 in DWNN) are highly, although
not absolutely, conserved.
A number of lines of evidence suggest a role for RBBP6 in
both mRNA processing and ubiquitin-like protein modi-
fication. The close association between domains involved
in RNA metabolism and ubiquitination has previously
been pointed out in a number of proteins, including
MDM2 [24]. In yeast, the RBBP6 homologue Mpe1p has
been shown to be a component of the CPF complex [11].
Mammalian RBBP6 has been identified as an SR protein
on the basis of an SR domain (residues 477–570) [2], the
CCHC RNA binding domain, its localisation within
nuclear speckles [9] and its associate with heterogeneous
nuclear ribonucleoproteins (hnRNPs) [3]. SR proteins are
involved in splicing, whereas hnRNPs are thought to play
a central role in organising the polyadenylation, splicing
and export of mRNA transcripts [36]. A number of SR pro-
teins are known to interact directly with the C-terminal
domain of the RNA Polymerase II complex. A role for
RBBP6 in mRNA processing therefore seems highly prob-
able. The presence of a RING finger domain in all eukary-
otes, combined with the ubiquitin-like structure of the
DWNN domain, makes it highly probable that RBBP6
also has ubiquitin-ligase activity, possibly involving mod-
ification of hnRNPs with a ubiquitin-like moiety. Several
hnRNPs have recently been shown to be SUMOylated
[37], which resulted in a decreased affinity of the hnRNP
for mRNA.
Furthermore, since p53 and Rb have both been shown to
bind to mammalian RBBP6, it is possible that RBBP6
plays a role in the regulation of these two proteins similar
to that played by MDM2 [38], suggesting a possible model
for the integration of the regulation of transcription, cell
cycle control and apoptosis. Given the fact that the
DWNN domain can be independently expressed in verte-BMC Structural Biology 2006, 6:1 http://www.biomedcentral.com/1472-6807/6/1
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brates, an interesting possibility is that the function of
RBBP6 is to DWNNylate other proteins.
Conclusion
We have shown that the DWNN domain represents a
novel ubiquitin-like domain expressed in vertebrates both
as a single domain protein and as the N-terminus of the
RBBP6 family of tumour-suppressor associated proteins,
making this the first example of a ubiquitin-like domain
that is alternatively expressed both as a UBL and as a UBP.
Members of the RBBP6 family are found at low copy
number in all eukaryotes but not in prokaryotes, and the
N-terminal three domains (DWNN domain, CCHC zinc
knuckle and RING finger domain) are well conserved in
all eukaryotes. Longer forms are found in worms, flies and
vertebrates, and the human RBBP6 contains domains
known to interact with p53 and Rb.
The similarity of DWNN domain to ubiquitin and the
presence of the RING finger suggest that the DWNN
domain may act as an ubiquitin-like modifier, possibly
playing a role in the regulation of the splicing machinery.
Whether this involves the proteosome or some other
ubiquitin-associated signalling such as regulation of
membrane trafficking or protein sorting remains to be
determined.
The functional basis for the association with p53 and Rb
is less clear. Parallels have been drawn between the verte-
brate long form of RBBP6 and MDM2 [2,4] on the basis
that both proteins contain RING domains and interact
with p53 and Rb. This would suggest a role for RBBP6 in
the regulation of the cell cycle and apoptosis and the inte-
gration of these processes with transcription and mRNA
processing. The presence of the three domain form in even
the earliest eukaryotes would appear to support the con-
clusion that RNA metabolism is the primary role of the
protein, and that domains linking the protein to cell cycle
regulation were added after the divergence of animals
from plants and fungi.
Methods
Bioinformatics
Sequences related to the human DWNN domain were
identified using BLAST, using all publicly available
sequence data [REF BLAST]. 50 examples of DWNN
domains from a diverse range of eukaryotes were selected,
and sequence alignments were generated using ClustalX
[39]. Details of the sequences used in Figure 2 can be
found in Additional_data.doc: Table 1.
Sample preparation
The nucleotide sequence corresponding to residues 1–81
of human RBBP6 was amplified from the 21c4 cDNA [12]
NOE, chemical shift and coupling constant data used in the structure calculation Figure 3
NOE, chemical shift and coupling constant data used in the structure calculation. All NOE's were assigned auto-
matically using the CANDID module of CYANA. Cartoon representations of secondary structural elements are derived from 
the final family of structures. Coupling constants were extracted from a 15N-HMQC-J spectrum. Half-circles correspond to 
3JNα < 4 Hz; filled circles correspond to 3JNα > 8 Hz, except in the case of residues 56-7, which have 3JNα values of 7.4 and 7.7 
Hz respectively. These residues form part of strand β5, which is the least stable of the five strands making up the main β-sheet. 
The presence of a β-sheet comprised of strands β3 and β6, which does not occur in ubiquitin, is confirmed by large values of 
3JNα, negative Cα shifts and αN(i,i+1) NOE's. The diagram was generated using CYANA [45].
α β1 β2 β4 β5 β6 β7 β3
3JNαBMC Structural Biology 2006, 6:1 http://www.biomedcentral.com/1472-6807/6/1
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using the polymerase chain reaction with forward primer
5'-GAGGCGGGATCCATGTCCTGTGTGCATTATTAATTT-
TCC-3' and reverse primer 5'-GAGGCGCTCGAGTTAT-
CATTTAACACCTCCAATAGGAAT-3'. The amplified
fragment incorporated a Bam HI site at the N-terminus,
immediately preceding and in-frame with the initiation
methionine, and an Xho I site at the C-terminus. Two stop-
codons (TGA TAA) were inserted between the final codon
and the Xho I site to prevent read-through. The amplified
product was digested with Bam HI and Xho I and cloned
directly into a pGEX-6P-2 vector (GE Healthcare) which
had been previously digested with the same enzymes. 1
litre cultures of E. coli BL21 (DE3) pLysS cells transformed
with the plasmid were grown at 37°C until the OD550
reached 0.6, and expression of GST-DWNN fusion protein
induced by addition of 0.5 mM IPTG, followed by incuba-
tion overnight at 30°C. Cells were pelleted by centrifuga-
tion at 3000 × g for 20 mins and re-suspended in 10×
mass of Binding Buffer (PBS, 1% TritonX, 1 mM PMSF, 1
mM DTT, pH 7.4). Cells were lysed using the freeze-thaw
method (-70°C for 5 min followed by 37°C for 5 min,
repeated 3 times), centrifuged at 3000 × g for 30 mins at
4°C and the supernatant loaded onto a self-packed col-
umn containing 5 ml glutathione sepharose 4B beads
(SIGMA), operated under gravity. GST-DWNN fusion pro-
tein was eluted from the column in 5 ml fractions with
Elution Buffer (50 mM Tris, pH 8.0, 15 mM reduced glu-
tathione). Fractions containing the fusion protein were
dialised back into Cleavage Buffer (50 mM Tris, 150 mM
NaCl, 1 mM PMSF, 1 mM DTT, pH 8.0), which had the
additional effect of removing free glutathione, and
cleaved overnight at 4°C following addition of 1 unit of
PreScission™ Protease (GE Healthcare). Following cleav-
age, GST and PreScission™ Protease were removed by
passing the protein a second time down the glutathione
sepharose column, with DWNN being collected in the
flow-through. Final purification was achieved by concen-
trating the protein into 1 ml using a Centriprep YM-3 con-
centration device (Millipore) (MWCO 3000 Da), and
loading it onto an 80 cm self-packed Sephacryl S100 gel
filtration column (GE Healthcare), which had previously
been equilibrated with NMR buffer (100 mM Phosphate,
150 mM NaCl, 1 mM DTT, 0.02% Sodium Azide, pH 6.0).
Fractions containing pure DWNN were pooled and con-
centrated into 0.6 ml for NMR analysis. Despite numerous
attempts using a range of different buffers and pH's, we
were unable to immobilise the protein on either cation or
anion exchange. Protein concentrations were determined
Three dimensional structure of the DWNN domain Figure 4
Three dimensional structure of the DWNN domain. (A) Superposition of the 25 lowest energy conformers. (B) Car-
toon representation of the overall fold and secondary structure. The backbone adopts a ubiquitin-like β-grasp fold in which the 
central α-helix packs against a five-stranded β-sheet comprised of strands β1, β2, β4, β5 and β7. Unlike ubiquitin, DWNN con-
tains an additional double-stranded β-sheet at the N-terminal end of the central α-helix, comprising strands β3 and β6. (C) 
Superposition of the backbone traces of the DWNN domain (in blue) and ubiquitin (1UBI, in yellow). The RMSD over struc-
turally aligned regions between the two structures is 1.88 Å. (D) Structural alignment of the primary sequences of DWNN and 
ubiquitin, determined using the Dali server. The structurally equivalent regions comprise the following residues of DWNN: 2–
9, 11–20, 22–40, 44–50, 53–57, 59–64, 66–75. Molecular fitting, calculation of RMSD's and generation of figures were per-
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NOE's and RMSD's broken down by residue Figure 5
NOE's and RMSD's broken down by residue. (A) Distribution of NOE's as a function of residue. Long-range (|i-j|> = 5) – 
lilac bars; medium-range (1<|i-j|<5) – green bars; short-range (|i-j|< = 1) – yellow bars. NOE's are counted twice – once for 
each residue involved. (B) RMSD across the family of 25 structures, as a function of residue. Regions of secondary structure 
correlate well with low RMSD and large numbers of long-range NOE's.
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using the Bradford Assay [40] employing lysozyme as a
standard. Mass spectrometry was used to confirm that the
sample was homogeneous and that the protein had the
expected molecular weight (data not shown). The
expressed protein included five additional residues
(GPLGS) at the N-terminus resulting from the cloning
procedure; the numbering used in this report corresponds
to that in RBBP6.
NMR experiments
All NMR experiments were carried out at 298 K in aqueous
buffer (unless otherwise specified) using triple-resonance
probes equipped with z-gradients. A 13C-HSQC-NOESY
was recorded on a Bruker DRX900; a 15N-HMQC-J and a
2D NOESY spectrum in D2O were recorded on 500 MHz
and 750 MHz Oxford/GE spectrometers respectively; all
other spectra were recorded on a Varian Inova600. Spectra
were referenced such that the water resonance corre-
sponded to 4.753ppm. NMR spectra were processed using
the programme NMRPipe [41] and analysed using NMR-
View [42].
Sequential assignments were generated using
CBCA(CO)NH and CBCANH spectra, in conjunction
with a 15N-HSQC-TOCSY spectrum to aid in the identifi-
cation of residues. Side-chain assignments were generated
using H(C)CH-TOCSY and H(C)CH-COSY spectra. 3JNα
couplings were extracted from an HMQC-J spectrum [43]
and converted to φ dihedral angle restraints using the
standard Karplus relation. Restraints on φ and ψ angles
were also generated from N, HN, Hα, Cα, Cβ and CO chem-
ical shifts using the TALOS algorithm [44], and these were
combined with the coupling constant-derived restraints to
give a final set of dihedral restraints. NOE peak volumes
were extracted from the following spectra: 2D 1H-1H
NOESY in H2O, 2D 1H-1H NOESY in D2O, 3D 15N-
HSQC-NOESY and 3D 13C-HSQC-NOESY.
Structure calculations
Structure calculations combined with fully-automated
NOE assignment were performed using the CANDID
module of CYANA v2.0 [45,46]. Each iteration started
from a set of 100 random structures, with unassigned
NOE peak lists, chemical shift lists and dihedral angle
restraints as the only inputs. After each iteration the result-
ing NOE assignments were statistically analysed and used
to generate improved, spectrum-specific chemical shift
assignments for use in subsequent iterations. Un-assigned
NOE's were analysed manually in combination with
NOESY spectra and preliminary structures in order to
identify missing chemical shift assignments. The final set
of NOE-based restraints, together with dihedral restraints
for 90 residues, were used for refinement in explicit sol-
vent using CNS [47], according to the standard RECO-
ORD protocol [48]. Of 100 final structures the 25 lowest
energy structures were selected. Validation was carried
using WHATCHECK [27] and PROCHECK-NMR [28].
Using the Dali server [29] the following structurally equiv-
alent regions were defined between the DWNN domain
and human ubiquitin (PDB:1UBI): DWNN:2–9 ⇔
1UBI:1–8; DWNN:11–20 ⇔ 1UBI:9–18; DWNN:22–40
⇔ 1UBI:19–37; DWNN:42–50 ⇔ 1UBI:39–45;
DWNN:53–57  ⇔ 1UBI:46–50; DWNN:59–64 ⇔
1UBI:51–56; DWNN:66–75 ⇔ 1UBI:63–72. The RMSD
between the two structures was calculated using all back-
bone heavy atoms in the structurally equivalent regions.
The coordinates of the family of 25 structures have been
deposited in the PDB under accession number 2C7H.
Authors' contributions
DJRP and DJGR conceived of the study. DJRP coordinated
the project, participated in the NMR analysis and structure
calculations, and drafted the manuscript; EA carried out
the structure calculations; AF expressed the protein and
participated in the NMR analysis; PTL carried out the
molecular biology; EH collected the NMR data; DJGR per-
formed the bioinformatic analysis and helped with the
drafting of the manuscript.
Additional material
Acknowledgements
We would like to thank Prof Iain Campbell, Prof Rolf Boelens, Dr Alexan-
dre Bonvin and Dr Peter Sandor for valuable advice and hospitality during 
time spent in their laboratories. We would like to thank Dr Joern Werner 
for help with NMR data acquisition and Dr David Staunton for help with 
molecular biology.
References
1. Sakai Y, Saijo M, Coelho K, Kishino T, Niikawa N, Taya Y: cDNA
sequence and chromosomal localization of a novel human
protein, RBQ-1 (RBBP6), that binds to the retinoblastoma
gene product.  Genomics 1995, 30:98-101.
2. Simons A, Melamed-Bessudo C, Wolkowicz R, Sperling J, Sperling R,
Eisenbach L, Rotter V: PACT: cloning and characterization of a
cellular p53 binding protein that interacts with Rb.  Oncogene
1997, 14:145-155.
3. Witte MM, Scott RE: The proliferation potential protein-
related (P2P-R) gene with domains encoding heterogeneous
nuclear ribonucleoprotein association and Rb1 binding
shows repressed expression during terminal differentiation.
Proc Natl Acad Sci U S A 1997, 94:1212-1217.
4. Yoshitake Y, Nakatsura T, Monji M, Senju S, Matsuyoshi H, Tsu-
kamoto H, Hosaka S, Komori H, Fukuma D, Ikuta Y, Katagiri T, Furu-
kawa Y, Ito H, Shinohara M, Nakamura Y, Nishimura Y:
Proliferation potential-related protein, an ideal esophageal
Additional File 1
Accession numbers of all sequences used in the multiple alignment in Fig-
ure 2.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6807-6-1-S1.doc]BMC Structural Biology 2006, 6:1 http://www.biomedcentral.com/1472-6807/6/1
Page 11 of 12
(page number not for citation purposes)
cancer antigen for immunotherapy, identified using comple-
mentary DNA microarray analysis.  Clin Cancer Res 2004,
10:6437-6448.
5. Gao S, Witte MM, Scott RE: P2P-R protein localizes to the
nucleolus of interphase cells and the periphery of chromo-
somes in mitotic cells which show maximum P2P-R immu-
noreactivity.  J Cell Physiol 2002, 191:145-154.
6. Gao S, Scott RE: P2P-R protein overexpression restricts
mitotic progression at prometaphase and promotes mitotic
apoptosis.  J Cell Physiol 2002, 193:199-207.
7. Gao S, Scott RE: Stable overexpression of specific segments of
the P2P-R protein in human MCF-7 cells promotes camp-
tothecin-induced apoptosis.  J Cell Physiol 2003, 197:445-452.
8. Scott RE, Gao S: P2P-R deficiency modifies nocodazole-
induced mitotic arrest and UV-induced apoptosis.  Anticancer
Res 2002, 22:3837-3842.
9. Scott RE, Giannakouros T, Gao S, Peidis P: Functional potential of
P2P-R: a role in the cell cycle and cell differentiation related
to its interactions with proteins that bind to matrix associ-
ated regions of DNA?  J Cell Biochem 2003, 90:6-12.
10. Scott RE, White-Grindley E, Ruley HE, Chesler EJ, Williams RW:
P2P-R expression is genetically coregulated with compo-
nents of the translation machinery and with PUM2, a trans-
lational repressor that associates with the P2P-R mRNA.  J
Cell Physiol 2004.
11. Vo LT, Minet M, Schmitter JM, Lacroute F, Wyers F: Mpe1, a zinc
knuckle protein, is an essential component of yeast cleavage
and polyadenylation factor required for the cleavage and
polyadenylation of mRNA.  Mol Cell Biol 2001, 21:8346-8356.
12. Frigerio JM, Berthezene P, Garrido P, Ortiz E, Barthellemy S, Vasseur
S, Sastre B, Seleznieff I, Dagorn JC, Iovanna JL: Analysis of 2166
clones from a human colorectal cancer cDNA library by par-
tial sequencing.  Hum Mol Genet 1995, 4:37-43.
13. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lip-
man DJ: Gapped BLAST and PSI-BLAST: a new generation of
protein database search programs.  Nucleic Acids Res 1997,
25:3389-3402.
14. Katinka MD, Duprat S, Cornillot E, Metenier G, Thomarat F, Prensier
G, Barbe V, Peyretaillade E, Brottier P, Wincker P, Delbac F, El Alaoui
H, Peyret P, Saurin W, Gouy M, Weissenbach J, Vivares CP: Genome
sequence and gene compaction of the eukaryote parasite
Encephalitozoon cuniculi.  Nature 2001, 414:450-453.
15. Krishna SS, Majumdar I, Grishin NV: Structural classification of
zinc fingers: survey and summary.  Nucleic Acids Res 2003,
31:532-550.
16. Lopato S, Gattoni R, Fabini G, Stevenin J, Barta A: A novel family of
plant splicing factors with a Zn knuckle motif: examination
of RNA binding and splicing activities.  Plant Mol Biol 1999,
39:761-773.
17. Shomron N, Reznik M, Ast G: Splicing factor hSlu7 contains a
unique functional domain required to retain the protein
within the nucleus.  Mol Biol Cell 2004, 15:3782-3795.
18. Joazeiro CA, Weissman AM: RING finger proteins: mediators of
ubiquitin ligase activity.  Cell 2000, 102:549-552.
19. Albert TK, Lemaire M, van Berkum NL, Gentz R, Collart MA, Tim-
mers HT: Isolation and characterization of human orthologs
of yeast CCR4-NOT complex subunits.  Nucleic Acids Res 2000,
28:809-817.
20. Albert TK, Hanzawa H, Legtenberg YI, de Ruwe MJ, van den Heuvel
FA, Collart MA, Boelens R, Timmers HT: Identification of a ubiq-
uitin-protein ligase subunit within the CCR4-NOT transcrip-
tion repressor complex.  Embo J 2002, 21:355-364.
21. Fribourg S, Kellenberger E, Rogniaux H, Poterszman A, Van Dorsse-
laer A, Thierry JC, Egly JM, Moras D, Kieffer B: Structural charac-
terization of the cysteine-rich domain of TFIIH p44 subunit.
J Biol Chem 2000, 275:31963-31971.
22. Aravind L, Koonin EV: The U box is a modified RING finger - a
common domain in ubiquitination.  Curr Biol 2000, 10:R132-4.
23. Mather A, Rakgotho M, Ntwasa M: SNAMA, a novel protein with
a DWNN domain and a RING finger-like motif: a possible
role in apoptosis.  Biochim Biophys Acta 2005, 1727:169-176.
24. Anantharaman V, Koonin EV, Aravind L: Comparative genomics
and evolution of proteins involved in RNA metabolism.
Nucleic Acids Res 2002, 30:1427-1464.
25. Sattler M, Schleucher J, Griesinger C: Heteronuclear multidimen-
sional NMR experiments for the structure determination of
proteins in solution employing pulsed field gradients.  Progress
in Nuclear Magnetic Resonance Spectroscopy 1999, 34:93–158.
26. Koradi R, Billeter M, Wuthrich K: MOLMOL: a program for dis-
play and analysis of macromolecular structures.  J Mol Graph
1996, 14:51-5, 29-32.
27. Hooft RW, Vriend G, Sander C, Abola EE: Errors in protein struc-
tures.  Nature 1996, 381:272.
28. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton
JM: AQUA and PROCHECK-NMR: programs for checking
the quality of protein structures solved by NMR.  J Biomol NMR
1996, 8:477-486.
29. Holm L, Sander C: Protein structure comparison by alignment
of distance matrices.  J Mol Biol 1993, 233:123-138.
30. Schwartz DC, Hochstrasser M: A superfamily of protein tags:
ubiquitin, SUMO and related modifiers.  Trends Biochem Sci
2003, 28:321-328.
31. Wilkinson CR, Dittmar GA, Ohi MD, Uetz P, Jones N, Finley D:
Ubiquitin-like protein Hub1 is required for pre-mRNA splic-
ing and localization of an essential splicing factor in fission
yeast.  Curr Biol 2004, 14:2283-2288.
32. Ramelot TA, Cort JR, Yee AA, Semesi A, Edwards AM, Arrowsmith
CH, Kennedy MA: Solution structure of the yeast ubiquitin-like
modifier protein Hub1.  J Struct Funct Genomics 2003, 4:25-30.
33. Weissman AM: Themes and variations on ubiquitylation.  Nat
Rev Mol Cell Biol 2001, 2:169-178.
34. Passmore LA, Barford D: Getting into position: the catalytic
mechanisms of protein ubiquitylation.  Biochem J 2004,
379:513-525.
35. Haglund K, Di Fiore PP, Dikic I: Distinct monoubiquitin signals in
receptor endocytosis.  Trends Biochem Sci 2003, 28:598-603.
36. Reed R, Magni K: A new view of mRNA export: separating the
wheat from the chaff.  Nat Cell Biol 2001, 3:E201-4.
37. Li T, Evdokimov E, Shen RF, Chao CC, Tekle E, Wang T, Stadtman ER,
Yang DC, Chock PB: Sumoylation of heterogeneous nuclear
ribonucleoproteins, zinc finger proteins, and nuclear pore
complex proteins: a proteomic analysis.  Proc Natl Acad Sci U S
A 2004, 101:8551-8556.
38. Hsieh JK, Chan FS, O'Connor DJ, Mittnacht S, Zhong S, Lu X: RB reg-
ulates the stability and the apoptotic function of p53 via
MDM2.  Mol Cell 1999, 3:181-193.
39. Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ: Mul-
tiple sequence alignment with Clustal X.  Trends Biochem Sci
1998, 23:403-405.
40. Bradford MM: A rapid and sensitive method for the quantita-
tion of microgram quantities of protein utilizing the princi-
ple of protein-dye binding.  Anal Biochem 1976, 72:248-254.
41. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A: NMR-
Pipe: a multidimensional spectral processing system based
on UNIX pipes.  J Biomol NMR 1995, 6:277-293.
42. Johnson BA, Blevins RA: NMRView: A computer program for
the visualization and analysis of NMR data.  J Biomolecular NMR
1994, 4:603-614.
43. Forman-Kay JE, Gronenborn AM, Kay LE, Wingfield PT, Clore GM:
Studies on the solution conformation of human thioredoxin
using heteronuclear 15N-1H nuclear magnetic resonance
spectroscopy.  Biochemistry 1990, 29:1566-1572.
44. Cornilescu G, Delaglio F, Bax A: Protein backbone angle
restraints from searching a database for chemical shift and
sequence homology.  J Biomol NMR 1999, 13:289-302.
45. Guntert P, Mumenthaler C, Wuthrich K: Torsion angle dynamics
for NMR structure calculation with the new program
DYANA.  J Mol Biol 1997, 273:283-298.
46. Herrmann T, Guntert P, Wuthrich K: Protein NMR structure
determination with automated NOE assignment using the
new software CANDID and the torsion angle dynamics algo-
rithm DYANA.  J Mol Biol 2002, 319:209-227.
47. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-
Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ,
Rice LM, Simonson T, Warren GL: Crystallography & NMR sys-
tem: A new software suite for macromolecular structure
determination.  Acta Crystallogr D Biol Crystallogr 1998, 54 ( Pt
5):905-921.
48. Nederveen AJ, Doreleijers JF, Vranken W, Miller Z, Spronk CA, Nab-
uurs SB, Guntert P, Livny M, Markley JL, Nilges M, Ulrich EL, Kaptein
R, Bonvin AM: RECOORD: a recalculated coordinate databasePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Structural Biology 2006, 6:1 http://www.biomedcentral.com/1472-6807/6/1
Page 12 of 12
(page number not for citation purposes)
of 500+ proteins from the PDB using restraints from the
BioMagResBank.  Proteins 2005, 59:662-672.
49. Johnson JM, Mason K, Moallemi C, Xi H, Somaroo S, Huang ES: Pro-
tein family annotation in a multiple alignment viewer.  Bioin-
formatics 2003, 19:544-545.